Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed versus PRN Ozurdex dosing in refractory diabetic macular oedema
2012-003661-17Phase 3Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Sep 2012
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ozurdex in diabetic macular edema (DME) (2 arms), sponsored by Moorfields Eye Hospital. Primary endpoint: Change from baseline in best corrected visual acuity at 12 months. Started Sep 2012; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2012-003661-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003661-17.